What the research found

The ADVOCATE trial, published in 2021, compared avacopan (a C5a receptor inhibitor) against prednisone tapering in patients with ANCA-associated vasculitis. According to the FDA's investigation, the trial's primary efficacy endpoint was not met at week 52 (p = 0.1025). Rather than reporting this null result, company employees identified nine patients whose outcome assessments were re-evaluated after the database had been unblocked—a process conducted without the knowledge of the trial's academic co-authors. After these reassessments, the headline result became statistically significant, leading to FDA approval in October 2021.

The trial's academic authors subsequently requested retraction, confirming that endpoint re-adjudication occurred post-hoc and post-unblinding without their knowledge or disclosure. This represents the first retraction of a registrational study from NEJM in over 200 years, and the first rheumatology retraction in the journal's history.

Why it matters for you

If you've been tracking avacopan as part of a vasculitis management protocol, this fundamentally changes what we know about its efficacy. The evidence supporting its use has now been withdrawn—not because new safety data emerged, but because the original efficacy data were manipulated in ways that wouldn't have passed regulatory scrutiny if disclosed transparently.

More broadly, this case illustrates a systemic problem: a drug can move through FDA approval, get published in a top-tier journal, and remain on the market for years while the underlying data integrity goes undetected. The discovery only happened because shareholders noticed odd trial results and sued for securities fraud—not because standard scientific or regulatory oversight caught the problem. If you're evaluating any treatment (peptide-based, pharmaceutical, or supplement) where efficacy claims rest on a single pivotal trial, this should sharpen your skepticism about what "FDA approved" actually guarantees.

Caveats

  • The FDA's allegations of data manipulation have been confirmed by the trial's academic authors and led to retraction, but individual criminal or professional accountability for the company employees involved remains unclear as of the source date.
  • The mechanism that allowed re-adjudication to "land in avacopan's favor" is mentioned but not fully explained in this source.
  • The source does not detail whether safety signals have emerged post-approval, only efficacy fraud.